Forth Therapeutics, an Edinburgh, Scotland, and Cambridge, England, UK-based biotechnology company advancing next-generation precision therapeutics for fibrosis, launched with a funding of undisclosed amount.
Backers included Sofinnova Partners, and Old College Capital.
Forth Tx builds on research from Professor Neil Henderson, a world-renowned fibrosis and tissue regeneration expert. The company, which spun out of the University of Edinburgh and is led by CEO Alex Leech, a serial entrepreneur and Partner at Sofinnova Partners, who brings decades of company-building expertise, has developed a precision therapeutics platform that focuses on tackling fibrosis across multiple organ systems. Its portfolio includes three assets targeting key fibrosis pathways, underpinned by state-of-the-art omics technology.
FinSMEs
19/03/2025